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Arterial inflammaging highly contributes to cardiovascular morbidity and mortality. As vascular cells age they 
become senescent and sustain a chronic low grade sterile inflammation by acquiring a senescence-associated 
secretory phenotype (SASP). The molecular mechanisms leading to the phenotypic changes affecting endothelial 
cells (ECs) and vascular smooth muscle cells (VSMCs) are also relevant for the pathogenesis of vascular diseases, 
such as atherosclerosis and hypertension. Therefore, unravelling the etiology of vascular inflammaging becomes 
of crucial importance. MicroRNAs (miRNAs) are small non-coding negative post-transcriptional regulator that 
are emerging as promising drug targets. MicroRNA-34a (miR-34a) had been implicated in tissues aging and 
endothelial and endothelial progenitor cells senescence. Our recent work showed that this miRNA is upregulated 
in aged mouse aortas as well as in senescent VSMCs. Conversely, its target SIRT1 is downregulated in the same 
specimens. We also found that miR-34a can inhibit VSMCs proliferation and induce VSMCs senescence, the 
latter by the direct regulation of SIRT1. Notably, for the first time, we demonstrated that miR-34a is also able to 
modulate the SASP by inducing the transcriptional expression of a subset of pro-inflammatory factors in a 
SIRT1-independent manner. These data support a model in which the age-dependent upregulation of miR-34a, 
by affecting senescence and inflammation of vascular cells, could play a causal role to arterial dysfunctions. 
Hence, further studies are necessary to unravel miR-34a-dependent mechanisms leading to arterial 
inflammaging in order to develop an effective strategy for age-related cardiovascular complications. 
Keywords: miR-34a; Inflammaging; SIRT1; SASP; Vascular Aging 
To cite this article: Ileana Badi, et al. MicroRNA-34a: a new player in arterial inflammaging. RNA Dis 2015; 2: e757. doi: 
10.14800/rd.757. 
The term “inflammaging” was coined 15 years ago to 
describe the chronic, low-grade systemic inflammation that 
occurs during physiological aging in the absence of an overt 
infection [1]. Although inflammaging is a hallmark of all 
age-associated diseases and highly contributes to morbidity 
and mortality in the elderly population [1], its etiology 
remains largely unknown [2]. Thus, unravelling the molecular 
mechanisms which trigger and control inflammaging is 
extremely important, as it could help in the development of 
effective treatments for almost all the age-related diseases.  
Likewise arterial aging, that is an important risk factor for 
cardiovascular morbidity and mortality [3], begins with 
persistent low grade “sterile” inflammation [4] and cellular 
senescence is emerging as an important contributor to its 
maintenance via the acquisition of a senescence-associated 
secretory phenotype (SASP). Indeed, vascular cells release 
soluble molecules associated to inflammation, growth and 
extracellular matrix remodeling, such as cytokines 
chemokines, adhesion molecules, growth factors and 
proteases, that acting in an autocrine and paracrine manner, 
influence neighboring cells behavior altering their 
microenvironment [4, 5]. Both the main cell types constituting 
the arterial wall undergo these age-related phenotypic 
changes and the mechanisms that lead to these alterations, 
namely endothelial dysfunction and vascular smooth muscle 
cells (VSMCs) phenotypic shifts, are fundamental for the 
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pathogenesis of vascular diseases such as atherosclerosis and 
hypertension [4]. Therefore, elucidating the cellular and 
molecular processes underlying vascular inflammaging and 
related dysfunctions is of high scientific interest. 
MicroRNAs (miRNAs) are small non-coding RNA 
molecules that usually negatively regulate the 
post-transcriptional expression levels of multiple target genes 
and they are emerging as a promising class of drug targets [6]. 
MicroRNA-34a (miRNA-34a) was firstly described as a 
tumor suppressor miRNA, direct target of p53 that, when 
up-regulated, can induce apoptosis, cell cycle arrest and 
senescence in several cancers [7, 8]. Recently miRNA-34a 
expression have been shown to increase with age in different 
tissues and organs of humans and mice [9-11]. Notably, 
miR-34a levels increase with aging in human peripheral 
blood and murine plasma and peripheral blood mononuclear 
cells (PBMCs); furthermore, Schipper and colleagues found 
augmented miR-34a levels in PBMCs of patients with the 
inflammaging-associated Alzheimer’s disease compared to 
normal elderly controls [9, 12-14]. Concerning vascular cells, 
Ito and collaborators demonstrated that miR-34a can induce 
endothelial cells (ECs) senescence at least in part through the 
modulation of the longevity-associated SIRT1 gene [15] and 
Zhao and co-workers observed increased senescence and 
decreased SIRT1 protein levels upon miR-34a 
overexpression in endothelial progenitor cells [16]. However, 
the miR-34a role in whole aorta and specifically VSMCs 
aging and associated inflammation has been unexplored so 
far.  
We, therefore, undertook a study aimed to understand 
whether miR-34a could affect VSMCs senescence and their 
SASP [17]. Firstly, we demonstrated that miR-34a expression 
levels were increased in aged aortas of old mice compared to 
young animals while the contractile smooth muscle cells 
marker (SM22a) appeared downregulated. Interestingly, 
among all the assessed miR-34a targets (SIRT1, Bcl2 and 
Axl) only SIRT1 protein levels were significantly 
downregulated during aging. We also observed that SIRT1 
was expressed in both ECs and VSMCs in young aortas, 
while it was barely detectable in both cell types in the aged 
vessels. In accordance to the in vivo data, miR-34a 
expression increased whereas SIRT1 protein levels decreased 
during replicative senescence of cultured VSMCs. Moreover, 
overexpression of miR-34a in proliferative VSMCs caused at 
first, G0/G1 cell-cycle arrest along with p21 upregulation, 
followed by SIRT1 downregulation and senescence. While 
miR-34a-induced inhibition of VSMCs proliferation was 
SIRT1-independent, induction of cell senescence resulted, at 
least in part, directly regulated by this sirtuin. These results 
suggest that miR-34a could be an important player in 
vascular aging and its regulation of senescence as well as 
SIRT1 expression appear cell type-independent [15-17]. 
However, since a considerable number of genes involved in 
cellular growth and senescence are direct or indirect targets 
of miR-34a [18], it is unlikely that this miRNA can affect 
vascular aging only through SIRT1. Further studies are 
needed to shed more light on this aspect.  
Further, we demonstrated that miR-34a is not only a 
senescence-associated miRNA, but it may influence 
inflammaging also by modulating other processes than 
senescence, such as inflammation, and in particular VSMCs 
SASP [17]. Indeed, for the first time, we found that miR-34a 
could promote the expression of a subset of SASP molecules, 
specifically, the pro-inflammatory factors, IL1β, IL6, IL8, 
BMP2, and MCP1, and the soluble adhesion molecule 
ICAM1. In contrast, no effect was observed on growth 
factors and their regulators IGFBP4/6, GRO/α, and VEGF, 
and osteoprotegerin RNA levels. Accordingly, expression 
and secretion of pro-inflammatory SASP molecules have 
been found increased in VSMCs from aged animals as well 
as in replicative senescent VSMCs where the miR-34a is 
up-regulated [17, 19, 20]. Furthermore, a very recent work from 
Fan and colleagues supports our findings leading to a 
pro-inflammatory role for miR-34a in vascular cells; indeed, 
they showed that this miRNA is involved in the 
flow-dependent regulation of endothelial inflammation by 
affecting VCAM1 and ICAM1 expression in ECs and 
consequently monocyte adhesion [21]. 
The precise regulatory mechanisms responsible for SASP 
acquisition is currently unknown. In our in vitro experiments, 
the miR-34a-mediated transcriptional activation of 
pro-inflammatory SASP factors was not prevented by SIRT1 
ectopic overexpression. Interestingly, very recently, 
Hayakawa et al. demonstrated that in x-radiation-induced 
senescent human fibroblasts, depletion of SIRT1 enhanced 
the transcriptional levels of SASP components (IL6 and IL8) 
through epigenetic gene regulation [22]. The opposite was not 
observed in SIRT1 overexpression conditions [22]. Yet, 
although, the SIRT1 activator resveratrol has been shown to 
reduce the secretion of IL1β, MCP1 and IL6 by VSMCs [19, 
23], recently, Bollmann and colleagues demonstrated that 
resveratrol-dependent inhibition of cytokines expression 
occurs through the reduction of mRNA stability by the 
KH-type splicing regulatory protein (KSRP) activity and, is 
indeed, SIRT1-independent [24]. Moreover, other factors 
rather than SIRT1 have been implicating in SASP regulation. 
Csiszar and co-workers, for instance, showed that the 
secretion of IL1β, MCP1, TNFα and IL6 in aged VSMCs 
correlates with increased NF-κB activation [19]. Fan and 
colleagues showed that miR-34a affects ECs inflammation 
namely, VCAM1 and ICAM1 expression, through enhanced 
acetylation of the RelA/p65 subunit of NF-κB and thereby 
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activation of NF-κB signaling [21]. They also observed that 
miR-34a-induced expression of these cell adhesion 
molecules is partially prevented by SIRT1 [21]. Since SIRT1 
can regulate the acetylation of RelA/p65 subunit and thus 
decrease NF-κB activation [25], we speculate that in ECs 
miR-34a could influence NF-κB signaling at least partially 
via SIRT1. Hence, unrevealing the exact role of SIRT1 in 
SASP and whether miR-34a induces SASP factors 
expression in VSMCs by activating NF-κB or other pathways 
calls for further investigations.  
Taken together, all these experimental evidences indicate 
that miR-34a could be an important player in arterial 
inflammaging, since an age-dependent increase of its levels 
in vascular cells could enhance senescence and inflammation 
and thus cause arterial dysfunctions such as atherosclerosis. 
Accordingly, miR-34a expression has found augmented in 
human atherosclerotic lesions and in the aortas of an animal 
model of atherosclerosis [26, 27].  
Nonetheless, more studies are needed to deepen our 
knowledge on miR-34a involvement in arterial 
inflammaging, as this could be of extreme importance in 
order to develop an effective strategy beneficial for old 
people.  
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